Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6UDK

HIV-1 bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074

6UDK の概要
エントリーDOI10.2210/pdb6udk/pdb
関連するPDBエントリー6ORN
EMDBエントリー20175 20739 20740
分子名称RC1 variant of HIV-1 Env glycoprotein gp120, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (13 entities in total)
機能のキーワードhiv-1 broadly neutralizing antibody, bnab, env trimer, cryo-em, rc1, cd4-binding site, viral protein-immune system complex, viral protein/immune system
由来する生物種Human immunodeficiency virus 1 (HIV-1)
詳細
タンパク質・核酸の鎖数18
化学式量合計540021.82
構造登録者
Abernathy, M.E.,Barnes, C.O.,Gristick, H.B.,Bjorkman, P.J. (登録日: 2019-09-19, 公開日: 2020-01-29, 最終更新日: 2024-10-23)
主引用文献Schommers, P.,Gruell, H.,Abernathy, M.E.,Tran, M.K.,Dingens, A.S.,Gristick, H.B.,Barnes, C.O.,Schoofs, T.,Schlotz, M.,Vanshylla, K.,Kreer, C.,Weiland, D.,Holtick, U.,Scheid, C.,Valter, M.M.,van Gils, M.J.,Sanders, R.W.,Vehreschild, J.J.,Cornely, O.A.,Lehmann, C.,Fatkenheuer, G.,Seaman, M.S.,Bloom, J.D.,Bjorkman, P.J.,Klein, F.
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
Cell, 180:471-, 2020
Cited by
PubMed Abstract: Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, a new V1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) and potency (GeoMean IC = 0.048 μg/mL). Notably, 1-18 is not susceptible to typical CD4bs escape mutations and effectively overcomes HIV-1 resistance to other CD4bs bNAbs. Moreover, mutational antigenic profiling uncovered restricted pathways of HIV-1 escape. Of most promise for therapeutic use, even 1-18 alone fully suppressed viremia in HIV-1-infected humanized mice without selecting for resistant viral variants. A 2.5-Å cryo-EM structure of a 1-18-BG505 Env complex revealed that these characteristics are likely facilitated by a heavy-chain insertion and increased inter-protomer contacts. The ability of 1-18 to effectively restrict HIV-1 escape pathways provides a new option to successfully prevent and treat HIV-1 infection.
PubMed: 32004464
DOI: 10.1016/j.cell.2020.01.010
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.9 Å)
構造検証レポート
Validation report summary of 6udk
検証レポート(詳細版)ダウンロードをダウンロード

234136

件を2025-04-02に公開中

PDB statisticsPDBj update infoContact PDBjnumon